The biosimilar market is projected to reach $73 billion by 2030, but manufacturing these complex biologics presents challenges. Pharma companies must optimize processes, meet strict timelines, and reduce costs in a competitive landscape. As bioprocessing evolves, manufacturers must evaluate scale-up and scale-out strategies to maintain efficiency and manage risk in a market where “the process is the product.”
This webinar from Cytiva explores navigating these challenges and making informed decisions about manufacturing scenarios that impact cost of goods. Industry experts share insights on process economics and strategies to stay competitive while meeting market demands. Key topics include:
How scale-out scenarios impact cost of goods and factors to consider when scaling up or out
Why titer increases are a powerful lever for reducing costs
Balancing process optimization with risk management when adopting advanced bioprocessing technologies